Close Menu

NEW YORK (GenomeWeb) – Bayer and Foundation Medicine said today that they have entered a global collaboration to develop next-generation sequencing companion diagnostics, beginning with a test to identify patients eligible for treatment with larotrectinib (Vitrakvi), a TRK inhibitor now approved in the US for patients with NTRK fusions regardless of tumor type or location.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.